<DOC>
	<DOCNO>NCT02602873</DOCNO>
	<brief_summary>Tacrolimus recommend first line therapeutic medication within several immunosuppressive agent treat refractory pediatric nephrotic syndrome , definite efficacy low toxicity . But still key problem hinder use tacrolimus clinic , narrow therapeutic widow , great individual difference pharmacokinetics . Routine therapeutic drug monitoring ( TDM ) need practice . But disadvantage TDM hysteresis , could lead treatment failure toxicity . To find reason great pharmacokinetic difference patient find individual proper dosage administration important clinical use tacrolimus . It hot research tacrolimus organ transplant field , association gene polymorphisms cytochrome P-450 3A4 , 3A5 multiple drug resistant gene ( MDR1 ) concentration tacrolimus . However , study pharmacogenomics metabonomics tacrolimus patient nephrotic syndrome . The aim study relationship pharmacogenomics , metabonomics tacrolimus efficacy , toxicity blood concentration patient nephrotic syndrome , find exact dosage administration , provide reference individual drug administration .</brief_summary>
	<brief_title>Study Tacrolimus Used Pediatric Patients With Nephrotic Syndrome Based Pharmacogenomics Metabonomics</brief_title>
	<detailed_description>Investigators collect data efficacy adverse drug reaction ( ADR ) time efficacy evaluate , evaluate ADR , data demography , etc .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1. patient refractory nephrotic syndrome ; 2. patient age â‰¤14y . 1. patient sensitive steroid ; 2. combine therapy immunosuppressive agent ; 3. combine use drug maybe interact concentration tacrolimus ; 4. malignant disease , tumor .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>